ScoreWhy is Sarepta Therapeutics, Inc. ?
1
The company has declared negative results in Mar'2025 after 7 consecutive positive quarters
- NET PROFIT(HY) At USD -196.61 MM has Grown at -482.65%
- DEBT-EQUITY RATIO (HY) Highest at 40.79 %
- RAW MATERIAL COST(Y) Grown by 14.3% (YoY)
2
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -83.12%, its profits have fallen by -380.9%
3
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -83.12% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Sarepta Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Sarepta Therapeutics, Inc.
-81.89%
-0.81
104.22%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
40.69%
EBIT Growth (5y)
14.85%
EBIT to Interest (avg)
-8.03
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.54
Sales to Capital Employed (avg)
0.68
Tax Ratio
51.28%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
1.18%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.70
EV to EBIT
-41.31
EV to EBITDA
-77.97
EV to Capital Employed
2.75
EV to Sales
2.17
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-6.67%
ROE (Latest)
-13.99%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend21What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -300.75 MM
PRE-TAX PROFIT(Q)
At USD 116.92 MM has Grown at 761.14%
NET SALES(Q)
At USD 611.09 MM has Grown at 68.38%
DEBTORS TURNOVER RATIO(HY)
Highest at 4.95 times
NET PROFIT(Q)
Highest at USD 160.17 MM
EPS(Q)
Highest at USD 1.89
-17What is not working for the Company
NET PROFIT(HY)
At USD -196.61 MM has Grown at -482.65%
DEBT-EQUITY RATIO
(HY)
Highest at 40.79 %
RAW MATERIAL COST(Y)
Grown by 14.3% (YoY
CASH AND EQV(HY)
Lowest at USD 1,322.9 MM
INTEREST(Q)
Highest at USD 5.23 MM
Here's what is working for Sarepta Therapeutics, Inc.
Pre-Tax Profit
At USD 116.92 MM has Grown at 761.14%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 160.17 MM has Grown at 2,379.43%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD -300.75 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 611.09 MM has Grown at 68.38%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Profit
Highest at USD 160.17 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 1.89
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debtors Turnover Ratio
Highest at 4.95 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Depreciation
Highest at USD 14.86 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Sarepta Therapeutics, Inc.
Interest
At USD 5.23 MM has Grown at 16.1%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at 40.79 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Interest
Highest at USD 5.23 MM
in the last five periods and Increased by 16.1% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Cash and Eqv
Lowest at USD 1,322.9 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Raw Material Cost
Grown by 14.3% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
